Sacubitril valsartan sodium

Sacubitril valsartan sodium anhydrous is the anhydrous (water-free) form of the combination drug used to treat heart failure with reduced ejection fraction (HFrEF). It combines sacubitril, a neprilysin inhibitor that enhances natriuretic peptides for vasodilation and fluid balance, with valsartan, an angiotensin II receptor blocker (ARB) that reduces blood pressure and cardiac strain. The anhydrous form is used in pharmaceutical formulations where precise dosing and stability are critical. This combination improves heart function, reduces hospitalizations, and lowers the risk of cardiovascular death, and is marketed under the brand name Entresto. Its therapeutic use is listed as antihypertensives. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Sacubitril-Valsartan Trisodium Salt and Sacubitril-Valsartan Trisodium Salt 2.5hydrate. Its PubChem CID is 131801102.

CAS No 1898188-76-5
Molecular Formula C48H55N6Na3O8
Molecular Weight 913.0 g/mol
Synonyms trisodium;4-[[(2S,4R)-5-ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4-oxobutanoate;(2S)-3-methyl-2-[pentanoyl-[[4-[2-(1,2,3-triaza-4-azanidacyclopenta-2,5-dien-5-yl)phenyl]phenyl]methyl]amino]butanoate

Frequently Asked Questions